IDH1 and astrocytoma (excluding glioblastoma): Given the lack of strong evidence that WHO grade 3 is associated with a significantly worse patient outcome compared with WHO grade 2, IDH-mutant astrocytomas grades 2–3 are now often pooled into the single category “lower-grade IDH-mutant astrocytoma” in both clinical practice and research.